Danaher Corp views artificial intelligence in drug discovery as a long-term revenue driver, CEO Julie Montgomery said on Wednesday morning. The life sciences firm is positioning its instrument portfolio to capture growing adoption among pharmaceutical developers. Drugmakers increasingly turn to machine learning to streamline research and compress development timelines.

Building Blocks for AI Growth